Connect with us

Health & Wellness

Commission approves contract with BioNTech-Pfizer alliance to ensure access to a potential vaccine

Published

on

European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to request up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. Member States can decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.

Today’s contract with the BioNTech-Pfizer alliance builds upon the broad portfolio of vaccines to be produced in Europe, including the already signed a contracts with AstraZeneca, Sanofi-GSK and Janssen Pharmaceutica NV, and the concluded successful exploratory talks with CureVac and Moderna. This diversified vaccines portfolio will ensure Europe is well prepared for vaccination, once the vaccines have been proven to be safe and effective.

President of the European Commission, Ursula von der Leyen, said:  “In the wake of Monday’s promising announcement by BioNTech and Pfizer on the prospects for their vaccine, I’m very happy to announce today’s agreement with the European company BioNTech and Pfizer to purchase 300 million doses of the vaccine. With this fourth contract we are now consolidating an extremely solid vaccine candidate portfolio, most of them in advanced trials phase. Once authorised, they will be quickly deployed and bring us closer to a sustainable solution of the pandemic.”

Stella Kyriakides, Commissioner for Health and Food Safety, said: “A safe and effective vaccine is the only lasting exit strategy from the pandemic, and is at the centre of our European Vaccine Strategy. Today’s agreement follows the encouraging first indications from the clinical trial results and is further evidence of our commitment to putting more Europe in the area of health. It is a very telling example of what the EU can achieve when working together, as a Union, and a case in point of what a future European Health Union will be able to deliver.”

BioNTech is a German company working with US-based Pfizer to develop a new vaccine based on messenger RNA (mRNA). mRNA plays a fundamental role in  biology, transferring instructions from DNA to cells’ protein making machinery. In an mRNA vaccine, these instructions make harmless fragments of the virus which the human body uses to build an immune response to prevent or fight disease.

The Commission has taken a decision to support this vaccine based on a sound scientific assessment, the technology used, the companies’ experience in vaccine development and their production capacity to supply the whole of the EU.

Background

The European Commission presented on 17 June a European strategy to accelerate the development, manufacturing and deployment of effective and safe vaccines against COVID-19. In return for the right to buy a specified number of vaccine doses in a given timeframe, the Commission finances part of the upfront costs faced by vaccines producers in the form of Advance Purchase Agreements. Funding provided is considered as a down-payment on the vaccines that will actually be purchased by Member States.

Since the high cost and high failure rate make investing in a COVID-19 vaccine a high-risk decision for vaccine developers, these agreements will therefore allow investments to be made that otherwise might not happen.

Once vaccines have been proven to be safe and effective and have been granted market authorisation by the European Medicines Agency, they need to be quickly distributed and deployed across Europe. On 15 October, the Commission set out the key steps that Member States need to take to be fully prepared, which includes the development of national vaccination strategies. The Commission is putting in place a common reporting framework and a platform to monitor the effectiveness of national vaccine strategies.

The European Commission is also committed to ensuring that everyone who needs a vaccine gets it, anywhere in the world and not only at home. No one will be safe until everyone is safe. This is why it has raised almost €16 billion since 4 May 2020 under the Coronavirus Global Response, the global action for universal access to tests, treatments and vaccines against coronavirus and for the global recovery and has confirmed its interest to participate in the COVAX Facility for equitable access to affordable COVID-19 vaccines everywhere. As part of a Team Europe effort, the Commission announced is contributing with €400 million in guarantees to support COVAX and its objectives in the context of the Coronavirus Global Response.

Continue Reading
Comments

Health & Wellness

COVID-19 cases rise for first time in seven weeks

Published

on

A healthcare worker checks the temperature of a patient at a hospital in Nonthaburi Province, Thailand. UN Women/Pathumporn Thongking

After six consecutive weeks of decline, COVID-19 cases worldwide increased last week for the first time, the World Health Organization (WHO) said on Monday. 

Four of the agency’s six regions reported a rise in numbers, with Africa and the Western Pacific excluded. 

“This is disappointing, but not surprising”, said WHO chief Tedros Adhanom Ghebreyesus, speaking during his biweekly press briefing from Geneva. 

“Some of it appears to be due to relaxing of public health measures, continued circulation of variants, and people letting down their guard.” 

The jump in cases comes as the rollout of COVID-19 vaccines continues. 

“Vaccines will help to save lives, but if countries rely solely on vaccines, they’re making a mistake”, Tedros warned, underscoring the importance of basic public health measures such as testing, contact tracing, wearing masks and avoiding crowds. 

‘Encouraging’ signs 

Ghana and Côte d’Ivoire began vaccinating health care workers on Monday, becoming the first countries to benefit from a global mechanism for ensuring vaccine equity.   

Through the COVAX Facility, WHO and our partners are working to ensure every country can begin vaccination within the first 100 days of the year.  

COVAX will deliver 11 million doses to countries this week.  By the end of May, some 240 million doses will be allocated to 142 participating countries. 

Dr. Soumya Swaminathan, WHO’s Chief Scientist, pointed to “encouraging” signs as the world continues to gear up for what is the largest vaccine deployment in history. 

“We’ve seen early data from countries where vaccination campaigns started months ago, the impact that this is having on reducing hospitalizations, reducing deaths, particularly in the older age groups, amongst the vulnerable. We’ve even seen very encouraging data in reduction in infections among health care workers who have received the vaccine”, she said. 

“So, these are still early days, but the signs are encouraging; the safety profile is encouraging. About 250 million doses have been given worldwide, and so far, there have been no major safety signals, so that is reassuring as well.” 

Concern for Tigray region 

WHO explained that some countries have received COVAX vaccines early due to several factors such as the level of government preparedness, but logistical challenges in distributing vaccines, which include labelling, packaging and shipping, can also affect deployment. 

Dr. Michael Ryan, WHO Executive Director, spoke about the difficulty in reaching conflict areas such as the Tigray region in Ethiopia, where government and regional forces have been fighting since November. 

He said the situation is of grave concern, as water, sanitation, essential health services and COVID-19 intervention have been disrupted. Many people are living in displacement camps, increasing risk of diarrhoeal disease, malaria and other illneses. 

WHO has worked to provide essential supplies to cover 450,000 people, or roughly 10 per cent of the population, for three months, Dr. Ryan told journalists.  

“Our primary aim as an organization, wherever we work, is to ensure that all people have access to the basic, essential human right of access to basic health care”, he said. 

“We will work with the Ministry of Health; we will work with health cluster partners and anybody else who can help us to provide better access to the population there.” 

Continue Reading

Health & Wellness

Over 500,000 people have been inoculated against COVID-19 in Moscow

Published

on

The number of people who wish to receive a COVID-19 vaccination in Moscow has reached half a million, and over 500,000 of them have already received their first jab. Every day between 12,000 and 20,000 residents of the city sign up for vaccination.

Vaccines are being administered in 100 vaccination points in city polyclinics and 20 popular public places, where mobile teams have been deployed. The list of categories of citizens entitled to vaccination is constantly expanding and the city’s vaccination campaign is picking up pace.

The list of categories of citizens prioritized for vaccination also includes Muscovites over the age of 60 years old (who form the largest risk group and are most vulnerable to COVID-19). More than 9,000 residents of 33 retirement homes have already been vaccinated. In addition, vaccination is recommended for people with chronic diseases who need to stay at home, as well as college and university students over 18 years of age.

A convenient online vaccination appointments system has been set up specially for Muscovites in the mos.ru portal. It can be accessed by going to ‘Doctor’s Appointment’ in the list of services and selecting ‘Vaccination Against COVID-19’.

In addition, vaccine appointments can be made via the My Moscow mobile app, the Moscow Gosuslugi government services website and the emais.info medical services portal, as well as by calling a vaccination center. The vaccine is administered in two doses, with appointments for the second injection being made automatically.

Many large employers are requesting on-site vaccination of their staff, and this network will be gradually expanded. Naturally, the throughput capacity of such organizations and, most importantly, the employers’ wishes are being taken into account.

Detailed information on the vaccination program has also been posted in the portal’s special project.

The Sputnik V vaccine consists of two components requiring two injections, and provides a reliable immune response. Volunteers will first be injected with the first component of the vaccine, with a second vaccination following 21 days later. Only the first appointment needs to be booked, as the doctor will arrange the patient’s second visit on the day of their first vaccination. To ensure that people do not forget about their re-vaccination, they will receive an SMS message the day before it, reminding them of the date, time and clinic they need to attend.

The vaccination process takes at least an hour, including a 10-minute examination by a doctor before the vaccination and 15 minutes spent preparing the vaccine, which is stored in frozen state (with five doses in one vial) and thawed for five patients at once when they have been examined. Post-vaccination observation and examination take a further 30 minutes. Each patient receives a certificate recording the two injections and confirming that they have been vaccinated against the coronavirus.

The vaccine was produced using a biotechnological process based on the most modern technological platform created by Russian scientists. It is safe because it does not contain the coronavirus. It is based on special structures (carrier vectors) created in the laboratory that contain only a part of the virus gene. Upon encountering the vaccine, the human immune system produces protective antibodies.

Continue Reading

Health & Wellness

Natalia Vodianova joins UNFPA to tackle stigma and advance women’s health

Published

on

Russian supermodel and philanthropist Natalia Vodianova has been appointed as Goodwill Ambassador for the United Nations sexual and reproductive health agency, UNFPA. Photo: UNFPA

The UN’s sexual and reproductive health agency, UNFPA, on Wednesday appointed supermodel, philanthropist, and impact investor Natalia Vodianova as its newest Goodwill Ambassador, in an effort to empower women and girls, including fighting stigma surrounding menstruation.

“For too long, society’s approach to menstruation and women’s health has been defined by taboo and stigma”, said Ms. Vodianova, stressing that the situation “has undermined the most basic needs and rights of women.”

In her new role with UNFPA, officially known as the UN Population Fund, Ms. Vodianova will seek to help culturally redefine menstruation, as a normal bodily function.

On any given day, more than 800 million women and girls aged 15 to 49 are actively menstruating. In many countries, taboos surrounding the cycle leaves girls vulnerable and can even be life-threatening, says UNFPA, as they are excluded from public life, denied opportunities, sanitation and basic health needs.

Major mission

The agency said in a press release, that the issue has been starved of the attention it deserves, but in recent years that has started to change, and “achieving this, is central to UNFPA’s mandate”.

“It’s a tragic irony that something as universal as menstruation can make girls feel so isolated…We all have a role to play in breaking the taboos around menstruation”, said UNFPA Executive Director Natalia Kanem, underscoring the significance of spotlighting the damage caused.

She added that the agency “is pleased to partner with such a powerful and committed advocate. Societies prosper when girls are confident, empowered and making their own decisions!”

Building on past momentum

Over the past three years, Ms. Vodianova has teamed up with UNFPA to launch a series of “Let’s Talk” events worldwide, which have mobilised policy makers, civil society and the private sector to help tackle shame, exclusion and discrimination, faced routinely by millions of women and girls.

Leaders from various sectors such as fashion, politics, sport, technology and media have also gathered in Turkey, Kenya, Switzerland, Belarus and India to advance women’s health.

Raised in poverty by a single mother in Russia, along with caring for a half-sister who has cerebral palsy and autism, Ms.Vodianova is a passionate advocate for human rights, including reproductive rights and the rights of people living with disabilities, UNFPA noted.

The agency said it was looking forward to working with her in her role as a bridge builder across the fashion and technology industries, where she’s an influential international voice, to help achieve the Sustainable Development Goals by 2030.

Continue Reading

Publications

Latest

Trending